Recent research on clinical trial success rates that caught our eye:   We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they call Probability of Success ...

When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking.

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry.

This week we introduced the correlation between a company's biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper ...

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company's pipeline and the Company's Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also ...